REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/08/2026
Back to search
Official data from USPTO
CENTER FOR BREAKTHROUGH MEDICINES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CENTER FOR BREAKTHROUGH MEDICINES
ST13
US500000088981530Class
40, 42
Filing
88981530
Registration
6382057
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
06/09/2026
Trademark type
Word
Nice classes
40, 42
Filing date
12/12/2019
Registration date
06/08/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/08/2021
Last transaction
06/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/16/2021
First use in commerce
03/16/2021
Drawing code
4
Owner type
16
Owner location
KING OF PRUSSIA, PA, US
Examiner
STEEL, ALYSSA PALADINO
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
MORNING LIGHT IP, LLC
Representatives
Joshua M. Gerben, Esq. GERBEN LAW FIRM, PLLC
Technical classification
Nice Classes
Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Manufacturing services for others in the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banksplasmidsadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in humans and animals; manufacturing process consulting
Class 42
Research and development services in the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; scientific research and technical research servicesproduction of cell lines for others using lentivirus technology; scientific research and technical research services relating to producingassaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producingassayingpurifying adenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for otherscGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management servicesquality evaluation and analysisquality assurancequality controlin the fields of gene therapymodified gene therapycell therapytissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
Publications
History of USPTO decisions and trademark events.
37 publications found
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/19/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/08/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/06/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/05/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/03/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
05/03/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/26/2021
IUAF
USE AMENDMENT FILED
04/05/2021
DRRR
DIVISIONAL REQUEST RECEIVED
04/05/2021
EISU
TEAS STATEMENT OF USE RECEIVED
04/05/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
04/05/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/12/2021
PUBO
PUBLISHED FOR OPPOSITION
01/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/23/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/07/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/30/2020
GNRT
NON-FINAL ACTION E-MAILED
06/30/2020
CNRT
NON-FINAL ACTION WRITTEN
06/30/2020
DOCK
ASSIGNED TO EXAMINER
06/26/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
06/26/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
05/12/2020
ALIE
ASSIGNED TO LIE
04/28/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/22/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/22/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/21/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/21/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/16/2020
GNRT
NON-FINAL ACTION E-MAILED
03/16/2020
CNRT
NON-FINAL ACTION WRITTEN
03/16/2020
DOCK
ASSIGNED TO EXAMINER
03/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/16/2019
NWAP
NEW APPLICATION ENTERED
12/16/2019
Continuous trademark protection
Get notified about every new filing that threatens CENTER FOR BREAKTHROUGH MEDICINES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.